The announcement was made this morning in Latina and is part of a strategic plan which envisaged a growth in investments in Italy of 9.2% every year in the period 2019-2023, three times higher than the sector average pharmaceutical, according to a new study by The European House – Ambrosetti. This has translated into a 15% increase in employment in Italy over the last five years, reaching approximately 1,400 employees across the country.
«In the pharmaceutical panorama, Johnson & Johnson stands out for its strong attention to Research and Development (R&D) – it was clarified today – in the last five years, the company has invested almost 50 million euros in Italy (+11.7 % every year from 2019). Investments in R&D also foster a strong commitment to scientific research in the country. In 2023, Johnson & Johnson Innovative Medicine managed 114 clinical trials and collaborated with 993 research centers in Italy, offering access to care to more than 5,000 patients.”
The Latina site represents “an important part of Johnson & Johnson’s global supply chain” and currently produces more than four billion tablets a year, for around 30 different products. «97% of production is exported, reaching patients all over the world – explained the managers – The investment plan will allow an increase in production capacity of over 25%, as it will include innovative projects to support products in the development phase development and new production technologies, such as the Flex Line, to more efficiently manage the packaging of small production batches and a new continuous production line that will reduce the total end-to-end production time and allow drugs to reach patients more quickly.”
«The Johnson & Johnson plant in Latina, Italy, is experiencing a significant evolution – said the general manager of the Johnson & Johnson plant in Latina, Jorge Lopez – as we are strengthening our capabilities to serve a greater number of patients with innovative products. It has been recognized as a 4IR (Industry 4.0) site by the World Economic Forum due to our commitment to innovation and sustainability. This is a truly exciting time for our site. We have very passionate and committed people who focus on safety, quality and reliability as we work to deliver medicines to patients around the world every day.”
«Johnson & Johnson – added Oladapo Ajayi, vice president, Innovative Medicine Supply Chain of Johnson & Johnson – has a significant manufacturing presence throughout Europe and the Latina site is an important part of our global network. We continue to make significant investments in our Supply Chain to support the growth of our current portfolio of medicines and our pipeline of innovative solutions, which will allow us to continue providing products to the millions of patients around the world who rely on us every day ».
«Since 1975 – recalled Mario Sturion, managing director of Johnson & Johnson Innovative Medicine Italia – we have been a company strongly rooted in Italy. With this extraordinary investment we strengthen our concrete commitment to favor and increase the attractiveness and competitiveness of the country, strengthening excellent pharmaceutical research and production. We trust that innovation will continue to be welcomed and adequately recognised, that the clinical trials ecosystem will improve and become faster and that the constructive dialogue between institutions and industry, already started by the government, will continue and remain active. Every day we work together with all our stakeholders in the healthcare system to contribute to the development of the sector, with the aim of bringing innovation to our patients and to the National Health System.”
«Today’s event – the words of the Minister of Business and Made in Italy, Adolfo Urso – shows us how the pharmaceutical sector has become a new growth model for Made in Italy, thanks to the impressive investments in research and innovation. This growth, 60% driven by foreign companies, allows the local production fabric involved in the supply chain to grow equally and favors its internationalisation”. “It is – the government representative specified – a sector that can give great satisfactions for opening Italy to the world and bringing the world to Italy. Italy, following the European elections, has become the most reliable country at European level capable of attracting more and more foreign investments.”
«The pharmaceutical center of Lazio has a crucial role. It is a sector that focuses on quality – said the president of the Lazio Region, Francesco Rocca – as demonstrated by the level of personnel employed and the large investment in the research and development sectors. The objective for the future remains to further strengthen the pharmaceutical and biomedical sector and launch the Rome Technopole as a structural project, also thanks to the resources coming from the PNRR, thus giving new life to the industrial sector and at the same time building concrete responses to the health needs of people in the diagnostic and therapeutic fields”.
Satisfaction was also expressed by the president of the Senate Budget Commission, Nicola Calandrini: «Being able to boast the presence of a company of this scale in the Lazio region is extremely important for our community. Our challenge in the Budget Committee is to promote a different accounting of health spending in order to be able to consider part of the resources allocated to health protection as an investment and not as a current cost. We work, with the collaboration of all political forces, to achieve this objective, first of all at European level and then in the national context.”
«The announcement by Johnson & Johnson, which will invest 580 million euros in Italy over the next 5 years – highlighted the president of Farmindustria, Marcello Cattani – is further proof that the pharmaceutical industry as a whole continues to firmly believe in our Nation. It is no coincidence that production exceeded 50 billion euros, with exports of 49. Exports which in Latina reached 2 billion in the first quarter of 2024, +41% compared to 2023, consolidating the first position in the country. In Italy, pharmaceutical employment, especially among young people and women, continues to grow, reaching 70,000 workers”. “Results are the result of investments, over 3.5 billion in total, which demonstrate the deep roots in the territory of international capital companies and national. With new rules capable of attracting investments, even more can be done. A path that the Italian government is following – he concluded – because it considers the Life Sciences sector important and strategic”.
© ALL RIGHTS RESERVED
Read the full article at
The messenger
